NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc is a clinical-stage life sciences company developing a novel intranasal drug delivery system and platform technology to treat brain cancers and other central nervous system (CNS) diseases by bypassing the Blood-Brain Barrier (BBB).
Funding history
About NEONC TECHNOLOGIES HOLDINGS, INC.
How much funding has NEONC TECHNOLOGIES HOLDINGS, INC. raised?
NEONC TECHNOLOGIES HOLDINGS, INC. has raised $98.3M in total funding. The most recent round was Series F.
Where is NEONC TECHNOLOGIES HOLDINGS, INC. headquartered?
NEONC TECHNOLOGIES HOLDINGS, INC. is headquartered in Los Angeles, CA.
What does NEONC TECHNOLOGIES HOLDINGS, INC. do?
NeOnc is a clinical-stage life sciences company developing a novel intranasal drug delivery system and platform technology to treat brain cancers and other central nervous system (CNS) diseases by bypassing the Blood-Brain Barrier (BBB).
What problem does NEONC TECHNOLOGIES HOLDINGS, INC. solve?
The Blood-Brain Barrier has historically prevented effective delivery of therapeutic agents to the brain, limiting treatment of CNS diseases like glioblastoma.
What's NEONC TECHNOLOGIES HOLDINGS, INC.'s solution?
A proprietary, patented drug delivery platform built around synthesized Perillyl Alcohol (POH) that transports therapeutics across the blood-brain barrier, embodied in products like NEO100 and NEO212.
What makes NEONC TECHNOLOGIES HOLDINGS, INC. different?
A patented POH-based delivery technology with clinical research support (e.g., intranasal NEO100 studies in recurrent gliomas) and analyst coverage (MAXIM initiated a Buy rating).
What makes NEONC TECHNOLOGIES HOLDINGS, INC. notable?
NeOnc was founded by Dr. Thomas Chen, a USC neurosurgery professor, and its CEO Amir Heshmatpour has personally invested roughly $1M in open-market share purchases of the company.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.